Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Orchid Pharma and Cipla Introduce New Antibiotic to Tackle Drug Resistance
In collaboration with Cipla Limited, Orchid Pharma aims to ensure broad distribution of this medication across India.
- By PharmaNews Live Desk
- New Delhi
- Jul 01, 2024
Orchid Pharma Limited, based in Chennai, has launched a new antibiotic, Cefepime-Enmetazobactam, approved for treating complicated Urinary Tract Infections (cUTI), Hospital-Acquired Pneumonia (HAP), and Ventilator-Associated Pneumonia (VAP).
This marks a significant development in India’s pharmaceutical sector, addressing global concerns over Antimicrobial Resistance (AMR).
In collaboration with Cipla Limited, Orchid Pharma aims to ensure broad distribution of this medication across India. The partnership leverages Orchid's drug development expertise and Cipla's extensive distribution network to facilitate timely access to the new antibiotic.
Mr. Manish Dhanuka, Managing Director of Orchid Pharma, emphasized the drug's role in conserving Carbapenems. "The introduction of Cefepime-Enmetazobactam offers an alternative to Piperacillin-Tazobactam, potentially prolonging the effectiveness of reserve drugs like Carbapenems," said Dhanukla.
Mr. Umang Vohra, Managing Director & Global CEO of Cipla, highlighted the global health impact, stating, "This partnership reinforces Cipla's commitment to combating AMR, ensuring access to innovative therapies for infectious diseases."
According to the official statement, both companies have committed to promoting responsible antibiotic use, collaborating closely with healthcare professionals to maximize therapeutic benefits while minimizing the risk of antimicrobial resistance.